NICE TAs

04/02/2026

TA1128: Targeted-release budesonide for treating primary IgA nephropathy

04/02/2026

TA1127: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer

28/01/2026

TA1126: natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

27/01/2026

TA972: sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)

27/01/2026

TA1125: pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)

27/01/2026

TA1124: concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)

26/01/2026

TA1123: Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)

21/01/2026

TA1122: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

14/01/2026

TA1121: Acoramidis for treating transthyretin amyloidosis with cardiomyopathy

13/01/2026

TA1117: Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

08/01/2026

TA1120: Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

07/01/2026

TA1118: Entrectinib for treating NTRK fusion-positive solid tumours (terminated appraisal)

07/01/2026

TA1119: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR or BR are suitable (MA partial review of TA663)

11/12/2025

TA1116: Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia

10/12/2025

TA1115: Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy

03/12/2025

TA1114: Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

03/12/2025

TA1113: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma

19/11/2025

TA1110: Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

12/11/2025

TA1109: Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

05/11/2025

TA1107: Delgocitinib for treating moderate to severe chronic hand eczema